List of Excipients in Branded Drug DICLOFENAC SODIUM AND MISOPROSTOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Greenstone LLC	DICLOFENAC SODIUM AND MISOPROSTOL	diclofenac sodium and misoprostol	59762-0028	CELLULOSE, MICROCRYSTALLINE
Greenstone LLC	DICLOFENAC SODIUM AND MISOPROSTOL	diclofenac sodium and misoprostol	59762-0028	CROSPOVIDONE
Greenstone LLC	DICLOFENAC SODIUM AND MISOPROSTOL	diclofenac sodium and misoprostol	59762-0028	HYDROGENATED CASTOR OIL
Greenstone LLC	DICLOFENAC SODIUM AND MISOPROSTOL	diclofenac sodium and misoprostol	59762-0028	HYPROMELLOSE
Greenstone LLC	DICLOFENAC SODIUM AND MISOPROSTOL	diclofenac sodium and misoprostol	59762-0028	LACTOSE

Generic Drugs Containing DICLOFENAC SODIUM AND MISOPROSTOL

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	diclofenac sodium and misoprostol	0591-0397	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	diclofenac sodium and misoprostol	0591-0397	CROSPOVIDONE
Actavis Pharma Inc	diclofenac sodium and misoprostol	0591-0397	HYDROGENATED CASTOR OIL
Actavis Pharma Inc	diclofenac sodium and misoprostol	0591-0397	HYPROMELLOSES
Actavis Pharma Inc	diclofenac sodium and misoprostol	0591-0397	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in DICLOFENAC SODIUM AND MISOPROSTOL?

# Of NDCs	Excipient
14	CELLULOSE, MICROCRYSTALLINE
12	CROSPOVIDONE
3	ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER
14	HYDROGENATED CASTOR OIL
5	HYPROMELLOSE

Excipient Strategy and Commercial Opportunities for Diclofenac Sodium and Misoprostol

Last updated: February 26, 2026

What is the current excipient landscape for Diclofenac Sodium and Misoprostol formulations?

Diclofenac sodium and misoprostol are combined in pharmaceutical products primarily for the treatment of gastrointestinal conditions and pain management. The excipient profile must support stability, bioavailability, and patient compliance.

Typical excipient components:

• Binders & Fillers: Microcrystalline cellulose, lactose monohydrate.
• Disintegrants: Croscarmellose sodium, sodium starch glycolate.
• Lubricants: Magnesium stearate, colloidal silicon dioxide.
• Coatings: Hydroxypropyl methylcellulose, polyethylene glycol.

Formulation considerations:

• Diclofenac sodium's acidity requires buffering agents such as sodium bicarbonate to reduce gastrointestinal irritation.
• Misoprostol's sensitivity to moisture necessitates desiccants or moisture barriers.
• The combination product often employs enteric coatings to mitigate gastric irritation caused by diclofenac and to protect misoprostol until absorption.

How do excipient choices influence formulation stability and bioavailability?

• Stability Enhancement: Use of antioxidants like ascorbyl palmitate to prevent oxidative degradation, especially for misoprostol.
• Gastrointestinal Tolerance: Buffering agents and enteric coatings reduce gastrointestinal side effects.
• Absorption Efficiency: Lipid-based excipients or surfactants can be integrated to enhance absorption of poorly soluble components.

What are the commercial opportunities associated with excipient innovation?

Patent-protected excipient formulations

Designing novel excipients or novel combinations can provide patent barriers. For example:

• Specialty coating technologies targeting specific release profiles.
• Excipient blends that further minimize gastrointestinal irritation.

Market differentiation

• Developing formulations with improved tolerability may command premium pricing.
• Extending shelf life through more stable excipient combinations alone offers market value.

Regulatory advantages

• Use of excipients with established safety profiles simplifies regulatory approval.
• Novel excipients that demonstrate bioequivalence can open new patent pathways.

Contract manufacturing and licensing

Many pharmaceutical companies seek specialized excipient formulations. Outsourcing development can create licensing revenue streams.

How do regulatory trends impact excipient strategies?

• Increasing focus on excipients' safety profiles prompts the adoption of GRAS (Generally Recognized As Safe) ingredients.
• Regulatory bodies like the FDA and EMA emphasize excipient transparency in labeling.
• Innovations in excipients that support controlled or targeted release are favored, especially for combination drugs.

What is the potential for innovation in excipient technology for Diclofenac Sodium and Misoprostol?

• Functional excipients: Compounds offering multiple benefits like stabilization, controlled release, and taste masking.
• Biodegradable coatings: Environmentally friendly options compatible with oral formulations.
• Advanced delivery systems: Multi-layered or multi-compartment tablets with compartment-specific excipients for staged release.

Summary table: Excipient strategies and commercial opportunities

Strategy	Description	Market Potential
Novel coating technologies	Enteric or controlled-release coatings	High, especially if patent-protected
Stabilizing excipients	Antioxidants, moisture barriers	Moderate, enhances shelf life
Excipient innovation licensing	Licensing new excipient blends	High, generates revenue
Patient-friendly formulations	Tastes masking, reduced gastrointestinal irritation	Moderate, improves compliance

Key insights

• Excipients directly influence drug stability, efficacy, and tolerability.
• Innovation in excipient technology can create patent barriers, differentiate products, and extend market life.
• Regulatory landscapes favor safe, well-characterized excipients, but opportunities exist in developing targeted, controlled-release, or environmentally friendly options.
• Companies should explore novel coatings, stabilizers, and delivery platforms to maximize commercial gains.

FAQs

1. What excipients are most common in Diclofenac Sodium and Misoprostol formulations?
   Microcrystalline cellulose, lactose, croscarmellose sodium, magnesium stearate, hydroxypropyl methylcellulose, and sodium bicarbonate.

2. Can excipient innovation extend the patent life of a combined Diclofenac-Misoprostol drug?
   Yes. Novel excipient formulations and delivery systems can be patent-protected, extending market exclusivity.

3. What regulatory challenges exist in excipient innovations for these drugs?
   New excipients require safety validation, and regulatory authorities demand transparent documentation of safety and manufacturing data.

4. How does excipient choice impact gastrointestinal tolerability?
   Buffering agents and enteric coatings reduce irritation, improving tolerability and adherence.

5. Are there environmental considerations in excipient selection?
   Yes. Biodegradable and environmentally friendly excipients are increasingly scrutinized and preferred by regulators.

References

[1] EMA. (2021). Guideline on Excipients in the Dossiers for Application for Marketing Authorization of Human Medicinal Products. European Medicines Agency.

[2] FDA. (2020). Guidance for Industry: Excipients in Drug Products. U.S. Food and Drug Administration.

[3] Robinson, J. R., & Lee, V. H. (2018). Modern Pharmaceutics (4th ed.). CRC Press.

[4] USP. (2022). <1078> Excipients. United States Pharmacopeia.

[5] Weller, D. (2019). Advances in oral drug delivery systems: The role of excipients. Journal of Pharmaceutical Sciences, 108(4), 1381–1390.